Iteos Therapeutics Inc 's ROA from the second quarter of 2025 to the second quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Iteos Therapeutics Inc 's ROA in the second quarter of 2025?
Iteos Therapeutics Inc recorded a cumulative net loss of $-202 million during 12 months ending in the second quarter of 2025, resulting in a negative return on assets (ROA) of -30.26%.

However, within the Healthcare sector 454 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2025 from 3589 to 3787.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter
Y / Y Total Assets Change	-17.3 %	4.29 %	2.77 %	6.36 %	6.31 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-202	-131	-134	-121	-108
Return On Assets (TTM)	-30.26 %	-18.65 %	-19.35 %	-17.57 %	-15.92 %
ITOS's Total Ranking	# 3787	# 3589	# 4185	# 3644	# 3619
Total Assets (TTM) in million	619	654	684	720	748
Seq. Total Assets Change	-5.39 %	-4.37 %	-5 %	-3.78 %	19.31 %
Seq. Net Income Change	-	-	-	-	-

ITOS's 5 Years Annual ROA >> Back to ITOS Management Effectiveness >> Compare ITOS ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 53
Sector	# 455
Overall	# 3735

Return On Assets Statistics
High	Average	Low
40 %	0.14 %	-30.08 %
(Mar 31 2022)		(Jun 30 2025)

Financial Statements
Iteos Therapeutics Inc 's Assets	$ 619 million	ITOS's Balance sheet
Iteos Therapeutics Inc 's Income	$ -79 million	Quarterly ITOS's Income Statement
ITOS's Income by Division		See ITOS's Income by Division

Annual Return On Assets	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020
Y / Y Total Assets Change	2.77 %	-11.78 %	-14.77 %	158.77 %	-
Total Assets in million	684	665	754	885	342
Y / Y Net Income Change	-	-	-54.95 %	-	-
Net Income in million	-134	-113	97	215	-38
Annual Return On Assets	-19.66 %	-16.93 %	12.82 %	24.25 %	-11.12 %

ITOS's 5 Years Annual ROA >> Back to ITOS Management Effectiveness >> Compare ITOS ROA to its Competitors

More Return On Assets Ratios
ITOS's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ITOS's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ITOS's Competitors
Subscribers only: Roa for Iteos Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for ITOS's Customers

You may also want to know
ITOS's Roi	ITOS's Inventory Turnover Ratio	ITOS's Growth Rates	ITOS's Dividend Comparisons
	ITOS's Profitability Ratios	ITOS's Asset Turnover Ratio	ITOS's Dividend Growth
ITOS's Roe	ITOS's Valuation Ratios	ITOS's Financial Strength Ratios	ITOS's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2025, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:22:15+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.